CREATININE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
113.0 -1.2 1 3 59.0 0 0.5
UNII
AYI8EX34EU
CAS
60-27-5
SYNONYMS
  • 1-Methylglycocyamidine
  • Nsc-13123
  • Creatinine
  • 2-Imino-1-Methylimidazolidin-4-One
  • 1-Methylhydantoin-2-Imide
  • Creatinine [mart.]
  • Creatinine [mi]
  • 1-Methylhydantoin-2-Imide [inci]
  • Kreatininum
  • Creatinine [ii]
  • Creatinine [usp-Rs]
  • Creatinine [who-Dd]
ZINC ID(s)
Availability
Present in 69 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT00005766 Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis Phase 2 Completed
NCT02280070 2013-09-01 RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301). Phase 2 Recruiting
NCT01909141 2013-08-01 Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS Phase 0 Completed
NCT00323128 2006-05-01 Validation of Serum Creatinine Dosage and Renal Clearance Phase 1 Completed
NCT00178425 2005-01-01 PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients Phase 4 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Auricular (otic) Solution 0.5%
Im - Iv Injection 0.8%
Im - Iv - Sc Injection
Intra-Articular Injection 0.8%
Intra-Articular Injection, Sustained Action
Intrabursal Injection
Intradermal Injection, Sustained Action
Intralesional Injection 0.8%
Intralesional Injection, Sustained Action
Intramuscular Injection 0.5%
Intramuscular Injection, Sustained Action
Intrasynovial Injection 0.8%
Intrasynovial Injection, Sustained Action
Ophthalmic Solution 0.5%
Ophthalmic Solution, Drops 0.2%
Soft Tissue Injection 0.8%
Topical Emulsion, Cream

More Information

Usage Over Time

Comments